Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Name||indolent plasma cell myeloma|
|Definition||A multiple myeloma that is characterized by M protein in serum and/or urine and evidence of organ damage related the plasma cell neoplasm.|
|Path||disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm multiple myeloma indolent plasma cell myeloma|
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04497961||Phase II||Daratumumab Lenalidomide||A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide||Recruiting||USA||0|
|NCT05005299||Phase I||Cyclophosphamide + Fludarabine + Venetoclax||Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY)||Recruiting||1|
|NCT05400122||Phase I||Aldesleukin + TEW 7197 Cyclophosphamide + Fludarabine||Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer||Recruiting||USA||0|